Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
As we count down the remaining days until the launch of this global event in Kraków, Poland, ADI is proud to share a message from our CEO, Paola Barbarino, and highlight some of our key speakers joining us from 24-26 April 2024.
ADI is pleased to welcome both Her Majesty The Queen Sofía of Spain and Her Royal Highness Princess Muna Al Hussein of Jordan to ADI’s 36th International Conference
ADI welcomes three new Alzheimer associations, as well as new members to the ADI board.
ADI releases a position paper on the difficult decisions people with dementia, their families and carers are having to make around hospital admission and triage during COVID-19.
Professor Huali Wang of Alzheimer's Disease Chinese (ADC) explains how China has addressed the specific challenges of people living with dementia during COVID-19.
ADI's Global Perspective for February 2020 now available.
Roche announces end of DIAN-TU-001 study after it failed to meets its primary endpoint in people who are affected by early onset Autosomal dominant Alzheimer’s disease.
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI’s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer's Association Japan (AAJ) continue to work on progress made earlier in the year at the Osaka Summit.